A 58 year old man, who had mi,stented in 2016. Now fit and we'll. Active life

The risk of recurrent myocardial infarction (MI) in a 58-year-old man who had a coronary stent placed in 2016 and is currently healthy, active, with no mobility limitations, a normal BMI, on a normal diet, and no other apparent risk factors is generally reduced but not eliminated. Patients with a history of MI and stenting are at an increased baseline risk of recurrent cardiovascular events, including MI, compared to the general population even if currently healthy due to the underlying coronary artery disease NICE CKS.

Secondary prevention measures—including lifestyle modification, adherence to prescribed secondary prevention medications such as statins, antiplatelet therapy (e.g., aspirin and clopidogrel), beta-blockers, and ACE inhibitors—are critical to reducing this risk NICE CKS,NICE CKS,NICE CKS. Proper adherence to dual antiplatelet therapy (DAPT) after stenting is particularly important since premature discontinuation or inadequate response (e.g., clopidogrel resistance) significantly increases the risk of stent thrombosis and recurrent MI Cecchi et al. 2026.

Long-term risk is influenced by factors such as stent type and procedural factors: second-generation drug-eluting stents (DES) are associated with lower rates of stent thrombosis and recurrent events than first-generation DES or bare-metal stents Cecchi et al. 2026. In addition, intravascular imaging–guided stenting (e.g., IVUS) optimizes stent deployment and reduces early and late stent thrombosis risk Cecchi et al. 2026.

In a patient fitting the described profile—no additional risk factors, good functional status, and presumably good medication adherence—the risk of recurrent MI and stent thrombosis is expected to be lower than in patients with comorbidities such as diabetes, heart failure, reduced left ventricular function, renal impairment, or poor adherence NICE CKS,Cecchi et al. 2026. However, a residual risk remains due to ongoing atherosclerotic disease and potential progression of coronary artery lesions NICE CKS.

Quantitatively, randomized controlled trials with clopidogrel in patients undergoing PCI and stenting demonstrated an approximate 14% relative risk reduction for major cardiovascular events including MI with continued secondary prevention therapy, but events still occurred in 4.6% of clopidogrel-treated patients over one year, reflecting non-zero residual risk SmPC Clopidogrel,SmPC Clopidogrel,SmPC Clopidogrel. Longer-term data indicate that stent thrombosis can occur even beyond 12 months, though less frequently with newer stents and optimal therapy Cecchi et al. 2026.

Therefore, the patient’s prognosis is favourable but not risk-free; ongoing follow-up, risk factor management, and adherence to evidence-based medical therapy remain essential to minimizing the risk of recurrent MI NICE CKS,Cecchi et al. 2026.